Even if you don’t develop heart disease, it’s still costing you. “You’re paying for cardiovascular disease whether you have it or not,” Heidenreich says. “You’re paying for it in your taxes and your health insurance premiums.” He estimates that the average person in the U.S. is paying $878 per year for the societal costs of heart disease.
BUT KEEP SPENDING YOUR HARD EARNED MONEY
In the U.S., all cardiovascular disease costs $273 billion each year, including heart conditions, stroke, peripheral artery disease, and high blood pressure. In fact, of all the money spent in the U.S. on health care, 17% goes toward treating cardiovascular disease, says Paul A. Heidenreich, MD, a cardiologist at the VA Palo Alto Health Care System in California and associate professor of medicine at Stanford University. Heart conditions such as heart failure, heart attack, bypasses, etc., account for nearly $96 billion of that total.
What are the costs per person? One study estimated that over the course of a person’s lifetime, the cost of severe coronary artery disease — the most common form of heart disease — is more than $1 million. That includes both direct and indirect costs.
The FDA, Chelation Therapy and the Cure for Heart Disease
Heart disease is the number one killer of Americans. It is predicted that the cost of treating heart disease for Americans will reach a staggering $800 billion per year by 2030. An inexpensive cure for heart disease exists, but the FDA has recently banned several companies from marketing this cure. “Cardio Crime” is an expose of how large institutions such as the AMA, AHA and FDA, will protect their self interest and stifle innovative health care therapies even if the evidence strongly points to safety and efficacy.
I do not know how far this book is right or wrong but I do know that the American model (now followed world wide) of medical therapeutics is an economic model where an old product can not be laid aside because a better and cheaper one is available.
Also good products have been withdrawn to realize the expenditure made on development of newer products that may be more costly or less suitable. Some of the examples are ban on DDT, newer and newer antibiotics, pain killers etc.
Most of the governments are more interested in the taxes they raise from pharma, chemical, insurance sectors (including many more) rather than health or well being of their citizens. There is therefore an urgent need to bring the decisions of regulatory bodies to grass roots (globally, as most countries follow US model of economy now days) of informed citizen consent from the hollowed ivory towers where expert committees meet.